key: cord-0880267-p1nssfsu
authors: Jaiswal, D. S. R.; Mehta, A.; Bhagwati, D. G.; Lakhchaura, M. R.; Aiyer, D. H.; Khamar, D. B. M.; Chakrabarti, D. S.
title: Innate Immune Response Modulation and Resistance to SARS-CoV-2 infection: A Prospective Comparative Cohort Study in High Risk Healthcare Workers
date: 2020-10-21
journal: nan
DOI: 10.1101/2020.10.20.20214965
sha: 01356d042f1213439cea6e6dcc8dcdd17bec47ea
doc_id: 880267
cord_uid: p1nssfsu

To evaluate ability of modulated innate immune response to provide resistance to development of symptomatic RT-PCR confirmed COVID-19, 96 inpatient front line health care workers (HCW) were cohorted in 1:2 ratio to receive TLR2 agonist (heat killed Mycobacterium w, Mw; n=32) as innate immune response modulator or observation (n=64). All were followed up for 100 days. The incidence of COVID-19 was 31 (32.3%) for the entire cohort, with only one developing COVID-19 in Mw group (3.1% vs 46.8%. protective efficacy - 93.33%, p=0.0001; 95% CI 53.3-99.1). Self-limiting local injection site reaction was the only side effect and was seen in 14 HCW. Findings from the study suggest the potential for providing resistance against novel pathogen like SARS-CoV-2 by modulating innate immune response.

performed the study. SRJ, AM, GB and HM collected the data. SRJ and SC analyzed the data; SRJ and SC wrote the manuscript. All the co-authors reviewed and approved the manuscript. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 21, 2020. . https://doi.org/10.1101/2020.10.20.20214965 doi: medRxiv preprint NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

To evaluate ability of modulated innate immune response to provide resistance to development of symptomatic RT-PCR confirmed COVID-19, 96 inpatient front line health care workers (HCW) were cohorted in 1:2 ratio to receive TLR2 agonist (heat killed Mycobacterium w, Mw; n=32) as innate immune response modulator or observation (n=64). All were followed up for 100 days. The incidence of COVID-19 was 31 (32.3%) for the entire cohort, with only one developing COVID-19 in Mw group (3.1% vs 46.8%.

protective efficacy -93.33%, p=0.0001; 95% CI 53.3-99.1). Self-limiting local injection site reaction was the only side effect and was seen in 14 HCW. Findings from the study suggest the potential for providing resistance against novel pathogen like SARS-CoV-2 by modulating innate immune response.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. intradermally in each arm on day 1 of the study (Mw group) and followed up for 100 days. 64 age matched HCWs from the rest of the hospital were enrolled in a control group. All HCW included in the study had a nasopharyngeal swab evaluated for SARS-CoV-2 by reverse transcriptase-polymerase chain reaction (RT-PCR), on development of symptoms suggestive of COVID-19 or following exposure to an infected person. Body temperature, pulse rate, oxygen saturation and self-reporting of symptoms was evaluated before and after each working day in the Mw group. 'Exposure' was defined as close contact with SARS-CoV-2 infected individuals without full protective gear. COVID-19 was graded as mild, moderate or severe as per WHO criteria. Subjects in the Mw group underwent two additional random . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 21, 2020. . https://doi.org/10.1101/2020.10.20.20214965 doi: medRxiv preprint SARS-CoV-2 specific RT-PCR evaluation 4 weeks apart. The study was approved by the institutional ethics committee.

The characteristics and outcomes of the Mw and control groups are detailed in Table 1 . The only side effect noted with Mw was injection site reactions (moderate to severe -4 ; mild -10 ), which were self-limiting and did not require any specific management.

The study period coincided with the peak of the pandemic in New Delhi and the high rate of COVID-19 seen in control group is in line with that reported in similar HCW 1 . The resistance to COVID-19 seen in the Mw group suggests that a TLR2 agonist Mw might be useful in providing protection to subjects at a high risk of exposure. It will be interesting to study its long-term protective efficacy. BCG, another approved immunomodulator is also being evaluated for the prevention of COVID-19, and it will be interesting to study its outcome as there are differences in the innate immune response generated by the two in terms of being a TLR agonist and in ligand presentation 4 . Specific immune changes like upregulation of adaptive natural killer cells are being investigated by our group 5 to understand the immune . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 21, 2020. . https://doi.org/10.1101/2020.10.20.20214965 doi: medRxiv preprint

Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study

Trained Innate Immunity, Epigenetics, and Covid-19

Mycobacterium indicus pranii mediates macrophage activation through TLR2 and NOD2 in a MyD88 dependent manner

Mycobacterium indicus pranii and Mycobacterium bovis BCG lead to differential macrophage activation in Toll-like receptor-dependent manner

mechanism responsible for resistance to COVID-19. This study provides an initial proof to the concept of modulating the innate immune response for providing resistance to novel pathogens like SARS-COV2 until the availability of vaccines. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 21, 2020. . https://doi.org/10.1101/2020.10.20.20214965 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 21, 2020. . https://doi.org/10.1101/2020.10.20.20214965 doi: medRxiv preprint